NEI Research News

The inflammatory molecule interleukin-17A (IL-17A) triggers immune cells that in turn reduce IL-17A’s pro-inflammatory activity, according to a new NEI study.

Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodies, or ACPAs, in human tear fluid.

Methotrexate and the more expensive mycophenolate mofetil performed similarly in a head-to-head clinical trial that compared the two drugs for treating noninfectious uveitis, an eye disease that accounts for up to 15% of blindness in the U. S.

A new study shows that the complement system, part of the innate immune system, plays a protective role to slow retinal degeneration in a mouse model of retinitis pigmentosa, an inherited eye disease.

Participants in a phase I/II clinical trial of a new enzyme-based treatment for severe dry eye disease experienced reduced signs of disease and discomfort, according to a paper in Translational Vision Science and Technology.

A research team at Massachusetts Eye and Ear has shown that microglia, the primary immune cells of the central nervous system—including the retina of the eye—serve as “gatekeepers,” or biosensors and facilitators, of neuroinflammation...

A signaling pathway controlled by transforming growth factor β (TGF-β) could be involved in the progression of age-related macular degeneration (AMD).

Researchers at the University of North Texas Health Science Center have shown that the MDM2 inhibitor class of drugs can treat uveitis in mice.

Delivery of corticosteroids directly into the eye is more effective than injections adjacent to the eye, according to results from a comparative clinical trial of macular edema in patients with noninfectious uveitis.

Research from MIT and Massachusetts Eye and Ear points to an autoimmune response as the driver of optic nerve damage in a mouse model of glaucoma.